The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The theca of follicule or follicular theca, develops as an outer layer of the ovarian follicle when the primary follicle becomes a secondary follicle. As the follicles continue to grow the theca becomes organized into two layers a theca interna and a theca externa. Theca cells are a group of endocrine cells in the ovary made up of stromal connective tissue surrounding the follicle. Their functions include promoting folliculogenesis and recruiting a single follicle during ovulation.
For example, phenanthrene has two Clar structures: one with just one aromatic sextet (the middle ring), and the other with two (the first and third rings). The latter case is therefore the more characteristic electronic nature of the two. Therefore, in this molecule the outer rings have greater aromatic character whereas the central ring is less aromatic and therefore more reactive. In contrast, in anthracene the resonance structures have one sextet each, which can be at any of the three rings, and the aromaticity spreads out more evenly across the whole molecule. This difference in number of sextets is reflected in the differing ultraviolet–visible spectra of these two isomers, as higher Clar pi-sextets are associated with larger HOMO–LUMO gaps; the highest-wavelength absorbance of phenanthrene is at 293 nm, while anthracene is at 374 nm. Three Clar structures with two sextets each are present in the four-ring chrysene structure: one having sextets in the first and third rings, one in the second and fourth rings, and one in the first and fourth rings. Superposition of these structures reveals that the aromaticity in the outer rings is greater (each has a sextet in two of the three Clar structures) compared to the inner rings (each has a sextet in only one of the three).
Paleolithic hunting and gathering people ate varying proportions of vegetables (including tubers and roots), fruit, seeds (including nuts and wild grass seeds) and insects, meat, fish, and shellfish. However, there is little direct evidence of the relative proportions of plant and animal foods. Although the term "paleolithic diet", without references to a specific timeframe or locale, is sometimes used with an implication that most humans shared a certain diet during the entire era, that is not entirely accurate. The Paleolithic was an extended period of time, during which multiple technological advances were made, many of which had impact on human dietary structure. For example, humans probably did not possess the control of fire until the Middle Paleolithic, or tools necessary to engage in extensive fishing. On the other hand, both these technologies are generally agreed to have been widely available to humans by the end of the Paleolithic (consequently, allowing humans in some regions of the planet to rely heavily on fishing and hunting). In addition, the Paleolithic involved a substantial geographical expansion of human populations. During the Lower Paleolithic, ancestors of modern humans are thought to have been constrained to Africa east of the Great Rift Valley. During the Middle and Upper Paleolithic, humans greatly expanded their area of settlement, reaching ecosystems as diverse as New Guinea and Alaska, and adapting their diets to whatever local resources were available.
Fast (rotary) potters' wheels enabled early mass production of pottery, but it was the use of the wheel as a transformer of energy (through water wheels, windmills, and even treadmills) that revolutionized the application of nonhuman power sources. The first two-wheeled carts were derived from travois and were first used in Mesopotamia and Iran around 3,000 BCE.
Food engineering is a scientific, academic, and professional field that interprets and applies principles of engineering, science, and mathematics to food manufacturing and operations, including the processing, production, handling, storage, conservation, control, packaging and distribution of food products. Given its reliance on food science and broader engineering disciplines, such as electrical, mechanical, civil, chemical, industrial and agricultural engineering, food engineering is considered a multidisciplinary and narrow field. Due to the complex nature of food materials, food engineering also combines the study of more specific chemical and physical concepts, such as biochemistry, microbiology, food chemistry, thermodynamics, transport phenomena, rheology, and heat transfer. Food engineers apply this knowledge to the cost-effective design, production, and commercialization of sustainable, safe, nutritious, healthy, appealing, affordable and high-quality ingredients and foods, as well as to the development of food systems, machinery, and instrumentation.
Sources: en.wikipedia.org
The shape of the light curve of these supernovae at intermediate to late-times corresponds to the decay via electron capture of 56Ni to cobalt-56 and ultimately to iron-56. Nickel-59 is a long-lived cosmogenic radionuclide; half-life 76,000 years. 59Ni has found many applications in isotope geology. 59Ni has been used to date the terrestrial age of meteorites and to determine abundances of extraterrestrial dust in ice and sediment. Nickel-78, with a half-life of 110 milliseconds, is believed an important isotope in supernova nucleosynthesis of elements heavier than iron. 48Ni, discovered in 1999, is the most proton-rich heavy element isotope known. With 28 protons and 20 neutrons, 48Ni is "doubly magic", as is 78Ni with 28 protons and 50 neutrons. Both are therefore unusually stable for nuclei with so large a proton–neutron imbalance. Nickel-63 is a contaminant found in the support structure of nuclear reactors. It is produced through neutron capture by nickel-62. Small amounts have also been found near nuclear weapon test sites in the South Pacific.
According to the Iraqi minutes from the meeting, examined in 2006 by the Parliamentary Commissioner for Standards Sir Philip Mawer and dismissed by Galloway as forgeries, Tariq Aziz, Naji Sabri and Saddam's personal secretary Abid Hamid Mahmud were in attendance as Galloway offered Saddam British staff to launch an English-language Iraqi satellite television channel, and said oil prices were having an impact on the income of the Mariam Appeal. In a radio interview given on the day following the discussion, Galloway said the Iraqi president was determined to show that his offer of readmitting the United Nations weapons inspectors into the country was sincere. Galloway said that the United States had nothing to lose by postponing its plans for invasion. In an 11 August article for The Mail on Sunday, Galloway wrote that Saddam "clearly understood that Iraq has to be seen to go the extra diplomatic mile" and that he expressed fondness for "everything quintessentially British". The piece was interpreted by the CNN as "the latest apparent charm offensive adopted by the Iraqi leader in the face of possible military action against it", and the British Foreign Office refused to consider the overtures. On 12 August, the Iraqi minister of information Muhammad Saeed al-Sahhaf rejected the return of the UN inspectors. In January 2003, Galloway met with Saddam Hussein and Tariq Aziz once more. His claim that the encounter was held in an underground bunker was later contradicted by the Iraqi president's interpreter.
Nematocysts inject venom into prey, and usually have barbs to keep them embedded in the victims. Most species have nematocysts. Spirocysts do not penetrate the victim or inject venom, but entangle it by means of small sticky hairs on the thread. Ptychocysts are not used for prey capture — instead the threads of discharged ptychocysts are used for building protective tubes in which their owners live. Ptychocysts are found only in the order Ceriantharia, tube anemones. The main components of a cnidocyte are:
GamePro stated that "Gearbox has done one hell of a job in creating not just an add-on for Half-Life, but a continuation of a masterpiece", praising both level design and story elements, but noted that it was a little too short. However, some critics dissented on the idea that Opposing Force was as influential as other reviewers made out. PC Zone stated that "the taste left in the mouth is a bitter one", noting that "Opposing Force is a few excellent ideas strung together by pedestrian Half-Life padding", but concluded that "it was still a good weekend's worth of entertainment". Eurogamer stated that Opposing Force still had similar problems to other expansion packs, commenting that "X amount of new content has been created and it is going to be cut into the old content in a linear way to make it look like an all new game", but noted that "fortunately though the new stuff in Opposing Force... is pretty damn good". Although praising the level design as the game's strongest point, the reviewer felt that "towards the end of the game... they were running out of development time". Reviewing for IGN, Vincent Lopez stated that the game "does a fantastic job of making you remember exactly why you enjoyed the original so much", but criticized this as the biggest drawback, commenting that "you may find yourself wishing for a more original experience", but concluded that "for good, and bad: it's good to be back".
=== Menstruation and fertility === The first menstrual bleeding is referred to as menarche, and typically occurs about two years after thelarche. The average age of menarche is 12½ in the United States. Most American females experience their first period at 11, 12 or 13, but some experience it earlier than their 11th birthday and others after their 14th birthday. In fact, anytime between 8 and 16 is normal. In Canada, the average age of menarche is 12.72, and in the United Kingdom it is 12.9. The time between menstrual periods (menses) is not always regular in the first two years after menarche. Ovulation is necessary for fertility, but may or may not accompany the earliest menses. In postmenarchal females, about 80% of the cycles were anovulatory in the first year after menarche, 50% in the third year and 10% in the sixth year. Initiation of ovulation after menarche is not inevitable. A high proportion of females with continued irregularity in the menstrual cycle several years from menarche will continue to have prolonged irregularity and anovulation, and are at higher risk for reduced fertility.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.